Contents 3 min read
Claim and source comparison
Modafinil: cognitive outcomes in healthy participants, US labeling and safety notices on pregnancy and contraception.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Systematic review / meta-analysis
In the 2015 Battleday and Brem review, outcomes varied by task in healthy people without sleep deprivation. Some complex tests improved, while basic attention and memory results were mixed.
Differences in tasks and methods limit conclusions about general or long-term cognitive benefit and the safety of unsupervised use.
Source 1 · Abstract read
Official safety summary
The US PROVIGIL label lists adult indications for wakefulness in specific sleep disorders and warnings about serious rash, hypersensitivity and psychiatric symptoms.
These indications apply to the US product. Modafinil does not treat airway obstruction in sleep apnea, and the label provides no indication for cognitive use in healthy people.
Source 5 · Official summary read
Official safety summary
Modafinil can reduce the effectiveness of steroidal contraception during treatment. The US PROVIGIL label specifies 1 month of precautions after stopping, and the UK MHRA notice specifies 2 months. The MHRA advises against use during pregnancy.
These durations come from different national documents. Local product information and professional assessment guide the choice of method for each patient.
Correction · 2026-11-11: The half-life measurement context was specified. Contraception intervals now identify their country and source.
⚠ Medication Requiring a Prescription
The US PROVIGIL product information describes modafinil as a controlled prescription medicine. For a specific product in Türkiye, verify authorization, prescribing conditions and approved indications in current TİTCK records and product information. This general explanation does not determine the legal status of nonprescription sales or personal use.
What is Modafinil?
Modafinil is a prescription wakefulness-promoting drug approved in the United States in 1998. The US PROVIGIL label covers excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder in adults. It does not treat the underlying airway obstruction in sleep apnea.
Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains.
Mechanism of Effect
The US PROVIGIL label states that the full mechanism promoting wakefulness is unknown. Dopamine-transporter binding and reuptake inhibition have been demonstrated; experimental findings involving other circuits are not established cognitive outcomes in humans.
Most mechanism findings in this section come from cell or animal experiments; they do not establish the same effects or clinical benefits in humans.
Clinical Evidence
Battleday and Brem (2015) published a systematic review of 24 studies in healthy, non-sleep-deprived people; it was not a quantitative meta-analysis. Some learning and complex-task measures improved, while simple-task findings were mixed. These results do not establish general or long-term cognitive superiority or a safe self-use protocol in healthy people.
Modafinil carries a risk of misuse. The US PROVIGIL label classifies it as a Schedule IV controlled substance and reports euphoric/stimulant effects in humans. Different pharmacology does not mean protection from dependence or safety of unsupervised use.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
Modafinil does not replace sleep and should follow the prescriber’s plan. No validated “two or three days a week” nootropic cycle exists. The PROVIGIL label warns about serious rash/Stevens–Johnson syndrome, angioedema, psychiatric symptoms and cardiovascular events. New rash, chest pain or psychosis/mania symptoms require stopping the medicine and immediate medical assessment.
- headache
- nausea
- insomnia
Modafinil can reduce the effectiveness of steroidal contraception during treatment. The US PROVIGIL label specifies 1 month of precautions after stopping, and the UK MHRA notice specifies 2 months. The MHRA advises against use during pregnancy.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Nootropic Cycling: Evidence and Limits
Tolerance, dependence and withdrawal are different phenomena. Breaks may be considered for some substances, but there is no validated cycling schedule for all nootropics.
Sources
- Battleday RM, Brem AK. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology, 25(11), 1865–1881. PubMed · PMID 26381811
- Minzenberg MJ, Carter CS. (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 33(7), 1477–1502. PubMed · PMID 17712350
- Müller U, et al. (2013). Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology, 64(5), 490–495. PubMed · PMID 22820554
- Volkow ND, et al. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA, 301(11), 1148–1154. PubMed · PMID 19293415
- US National Library of Medicine. PROVIGIL (modafinil): Prescribing Information and Medication Guide. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8 US National Library of Medicine · DailyMed
- Medicines and Healthcare products Regulatory Agency. (2020). Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. https://www.gov.uk/drug-safety-update/modafinil-provigil-increased-risk-of-congenital-malformations-if-used-during-pregnancy Medicines and Healthcare products Regulatory Agency
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
Modafinil affects the dopamine transporter and has a nonzero misuse/dependence risk. It is a controlled prescription medicine in the US. Follow the prescriber’s treatment plan rather than changing dose or frequency yourself; intermittent use is not a proven method of preventing dependence.
Controlled studies have not adequately established the efficacy and safety of these combinations in healthy people. Theoretical complementarity is not proven synergy or a recommendation to combine them.